NSAIDs: the emperor's new dogma?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 12912873.
- Also identified by PMC identifier 1773807.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The spectacular marketing success of the selective cyclooxygenase 2 (COX-2) inhibitors is largely based on efficacy comparable with conventional non-steroidal anti-inflammatory drugs (NSAIDs) with vastly improved gastrointestinal safety. The additional key to the marketing success is the purity and simplicity of the message-that is, COX-1 inhibition causes the gastrointestinal side effects of NSAIDs (COX-1 dogma) while COX-2 blocking confers the therapeutic benefits (COX-2 dogma). Adherence to the COX dogmas with development of COX-2 selective agents has undoubtedly benefited many patients, but ironically their scientific basis is now seriously challenged by experimentation.
Medical subject headings
- Anti-Inflammatory Agents, Non-Steroidal
- Cyclooxygenase Inhibitors
- Gastrointestinal Diseases